117 related articles for article (PubMed ID: 22225776)
1. Silencing of homeobox B9 is associated with down-regulation of CD56 and extrathyroidal extension of tumor in papillary thyroid carcinoma.
Kim JH; Kim YH; Han JH; Lee KB; Sheen SS; Lee J; Soh EY; Park TJ
Hum Pathol; 2012 Aug; 43(8):1221-8. PubMed ID: 22225776
[TBL] [Abstract][Full Text] [Related]
2. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells.
Scarpino S; Di Napoli A; Melotti F; Talerico C; Cancrini A; Ruco L
J Pathol; 2007 Aug; 212(4):411-9. PubMed ID: 17573672
[TBL] [Abstract][Full Text] [Related]
3. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
4. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
6. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
[TBL] [Abstract][Full Text] [Related]
8. The helix-loop-helix protein, Id-1, is overexpressed and regulates growth in papillary thyroid cancer.
Kebebew E; Treseler PA; Duh QY; Clark OH
Surgery; 2003 Aug; 134(2):235-41. PubMed ID: 12947323
[TBL] [Abstract][Full Text] [Related]
9. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases.
Wenig BM; Thompson LD; Adair CF; Shmookler B; Heffess CS
Cancer; 1998 Feb; 82(4):740-53. PubMed ID: 9477108
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of expression of bcl-2 protein in papillary carcinomas and papillary microcarcinomas of the thyroid gland.
Mitselou A; Peschos D; Dallas P; Charalabopoulos K; Agnantis NJ; Vougiouklakis T
Exp Oncol; 2004 Dec; 26(4):282-6. PubMed ID: 15627060
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma.
Cheng SP; Chi CW; Tzen CY; Yang TL; Lee JJ; Liu TP; Liu CL
Surgery; 2010 Jun; 147(6):847-53. PubMed ID: 20045163
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
13. c-Met expression in tall cell variant papillary carcinoma of the thyroid.
Nardone HC; Ziober AF; LiVolsi VA; Mandel SJ; Baloch ZW; Weber RS; Mick R; Ziober BL
Cancer; 2003 Oct; 98(7):1386-93. PubMed ID: 14508824
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
15. Expression and significance of c-met protein in papillary thyroid carcinoma.
Inaba M; Sato H; Abe Y; Umemura S; Ito K; Sakai H
Tokai J Exp Clin Med; 2002 Aug; 27(2):43-9. PubMed ID: 12472169
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas.
Furlan JC; Bedard YC; Rosen IB
J Am Coll Surg; 2004 Mar; 198(3):341-8. PubMed ID: 14992733
[TBL] [Abstract][Full Text] [Related]
18. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.
Asioli S; Erickson LA; Sebo TJ; Zhang J; Jin L; Thompson GB; Lloyd RV
Am J Surg Pathol; 2010 Jan; 34(1):44-52. PubMed ID: 19956062
[TBL] [Abstract][Full Text] [Related]
19. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
20. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]